Wuhan Porida Biotechnology

Wuhan Porida Biotechnology (also known as Bio-Raid) is a clinical-stage biopharmaceutical company based in Wuhan, China, specializing in the development of CAR-T cell therapies for cancer and infectious diseases. Founded in 2014 by Professor Zhang Tongcun, the company has established a comprehensive platform for CAR-T research, including GMP-compliant manufacturing for plasmids, lentiviruses, and cell products. Its lead candidate, BRD-01 (a CD30-targeted CAR-T), is currently in Phase 2 clinical trials for lymphoma and has received Orphan Drug Designation from the U.S. FDA. The company's pipeline also includes innovative programs targeting CD99, CD19/22, BCMA, and a unique CAR-T therapy for HIV (GP120). Wuhan Porida is recognized as a gold seed enterprise in Hubei province and is a pioneer in the clinical application of CAR-T technology in China.